B. De-pauw, T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin. Infect. Dis, vol.46, pp.1813-1821, 2008.

A. Alanio, J. L. Beretti, B. Dauphin, E. Mellado, G. Quesne et al., Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species, Clin. Microbiol. Infect, vol.17, pp.750-755, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-01405253

P. E. Verweij, S. J. Howard, W. J. Melchers, and D. W. Denning, Azoleresistance in Aspergillus: proposed nomenclature and breakpoints, Drug Resist Updat, vol.12, pp.141-147, 2009.

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin. Infect. Dis, vol.46, pp.201-211, 2008.

, Briefing document for voriconazole (oral and intravenous formulations), 2001.

V. V. Moudgal and J. D. Sobel, Antifungal drugs in pregnancy: a review, Expert Opin. Drug Saf, vol.2, pp.475-483, 2003.

W. Inman, P. G. , and W. L. , Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy, Eur. J. Clin. Pharmacol, vol.46, pp.115-118, 1994.

E. Lopez-rangel, V. Allen, and M. I. , Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype, Birth Defects Res. A Clin. Mol. Teratol, vol.73, pp.919-923, 2005.

T. J. Pursley, I. K. Blomquist, J. Abraham, H. F. Andersen, and J. A. Bartley, Fluconazole-induced congenital anomalies in three infants, Clin. Infect. Dis, vol.22, pp.336-340, 1996.

G. G. Briggs, R. K. Freeman, and S. J. Yaffe, Drugs in pregnancy and lactation, vol.1, 2008.